טוען...
Stopping paclitaxel premedication after two doses in patients not experiencing a previous infusion hypersensitivity reaction
PURPOSE: Paclitaxel-based chemotherapy continues to be an integral component of breast cancer treatment. Prolonged use of paclitaxel may result in repeated doses of premedications that can have unwanted side effects. Infusion hypersensitivity reactions occurring beyond the second dose of paclitaxel...
שמור ב:
| הוצא לאור ב: | Support Care Cancer |
|---|---|
| Main Authors: | , , , , , , , , , , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
2014
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4804339/ https://ncbi.nlm.nih.gov/pubmed/25519756 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00520-014-2556-x |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|